Goldman Sachs’s Longboard Pharmaceuticals, Inc. Common Stock LBPH Stock Holding History

Goldman Sachs’s Portfolio LBPH Stock Details LBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,026,703	Closed	-$34.2M	–	6402
2024 Q3	$34.2M	Buy	1,026,703 +701,760	+216%	+$24.2M	0.01%	1568
2024 Q2	$8.78M	Sell	324,943 -154,866	-32%	-$3.05M	﹤0.01%	2625
2024 Q1	$10.4M	Buy	479,809 +466,110	+3,403%	+$10.2M	﹤0.01%	2439
2023 Q4	$82.6K	Buy	13,699 +2,626	+24%	+$13.1K	﹤0.01%	5323
2023 Q3	$61.6K	Buy	11,073 +159	+1%	+$1.02K	﹤0.01%	5252
2023 Q2	$80.1K	Buy	+10,914	New	+$82.6K	﹤0.01%	5395
2021 Q2	–	Sell	-25,000	Closed	-$410K	–	6841
2021 Q1	$410K	Buy	+25,000	New	+$409K	﹤0.01%	5256

Goldman Sachs's LBPH Position: Q4 2024 in Review

Goldman Sachs sold out of Longboard Pharmaceuticals, Inc. Common Stock (LBPH) in Q4 2024, closing a stake of 1,026,703 shares — an estimated $34.2M sold.

Goldman Sachs first reported a position in LBPH in Q1 2021 and held it in 7 quarters. The position peaked at $34.2M in Q3 2024. 0 funds tracked by Wall St. Rank hold LBPH as of Q4 2024.

Goldman Sachs reported no remaining Longboard Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
Goldman Sachs sold 1,026,703 Longboard Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $34.2M.
Goldman Sachs first reported a position in Longboard Pharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 7 quarters.
Goldman Sachs's Longboard Pharmaceuticals, Inc. Common Stock position peaked at $34.2M in Q3 2024.
0 funds tracked by Wall St. Rank held Longboard Pharmaceuticals, Inc. Common Stock as of Q4 2024.

Based on Goldman Sachs's 13F filing for Q4 2024, filed 11 Feb 2025.